REGISTER
Huijuan Yuan Team: Seven Oral Presentations Accepted to EASD 2026
Seven oral presentations from Prof. Huijuan Yuan’s team at Henan Provincial People’s Hospital were accepted to EASD 2026 in Milan (Sept 28-Oct 2). Studies span gut microbiota in DKD, empagliflozin’s microbiota-mediated atherosclerosis protection, intermittent fasting for diabetic neuropathy, EOD-CKD burden (GBD 2021), sleep and CKM mortality, visceral adipocyte immunity, and a 36-RCT meta-analysis of intermittent vs continuous energy restriction (n=2,923).

At the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting 2026 in Milan, Italy (Sept 28 to Oct 2, 2026), seven oral presentations from the team led by Prof. Huijuan Yuan of the Department of Endocrinology and Metabolism at Henan Provincial People’s Hospital were accepted, addressing the burden of early-onset diabetes, cardiometabolic-kidney syndrome, and gut microbiota-targeted interventions for diabetes complications.

Article Key Points

- Seven oral presentations from Prof. Huijuan Yuan’s team accepted to EASD 2026 in Milan (Sept 28-Oct 2, 2026)

- Studies cover DKD microbiota, empagliflozin’s microbiota-mediated atherosclerosis effects, and intermittent fasting

- Additional studies include early-onset T2D CKD burden (GBD 2021), sleep and CKM mortality, visceral adipocyte immunity

- Meta-analysis (36 RCTs, n=2,923): intermittent energy restriction reduced weight by 1.02 kg vs continuous restriction

- Alternate-day fasting produced the largest weight loss (-1.83 kg); TRE may be less effective in older adults

- Evidence status: conference abstracts; full results have not yet been peer-reviewed

The Seven Presentations

1. Gut Microbiota and Metabolites Associated with Renal Injury in DKD

Authors: Yalei Liu, Binghua Xue, Jin Cao, Shasha Tang, Shihan Zhang, Huijuan Yuan (corresponding). Affiliation: Department of Endocrinology and Metabolism, Henan Provincial People’s Hospital.

Background: Diabetic kidney disease (DKD) is associated with gut dysbiosis, but whether dysbiosis directly contributes to renal injury is unclear. Methods: Case-control study of 51 DKD patients and 29 healthy controls (HC). Fecal samples underwent 16S rRNA sequencing and untargeted metabolomics; serum samples were tested for renal injury markers. Results: DKD patients showed significant changes in microbial alpha and beta diversity (P<0.05); beneficial genera (Bacteroides, Faecalibacterium, Prevotella, Roseburia, Dialister) were reduced, while Blautia, Enterococcus, and Ruminococcaceae_UBA1819 were enriched (all P<0.05). Metabolomics showed increased L-tryptophan and decreased cathasterone and secacalciferol (P<0.05). Serum CX3CL1, FGF-23, and TGF-beta were elevated in DKD (P<0.05). eGFR correlated positively with Prevotella abundance and negatively with L-tryptophan. The authors concluded that DKD patients exhibit gut dysbiosis, metabolite alterations, and elevated renal injury markers, suggesting a contribution of gut microbiota and metabolites to DKD-related renal injury.

2. Empagliflozin-Modified Gut Microbiota Improves Atherosclerosis in ApoE-/- Mice

Authors: Xinru Deng, Yujia Zhai, Huijuan Yuan (corresponding). Affiliation: Department of Endocrinology and Metabolism, Henan Provincial People’s Hospital.

Background: The cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors (SGLT-2i) are widely recognized, but mechanisms remain unclear. Building on prior work suggesting empagliflozin’s cardiovascular protection may involve gut microbiota, the team further examined whether empagliflozin improves atherosclerosis via the gut microbiota. Methods: Fecal suspensions from T2D patients before and after 3 months of empagliflozin plus metformin were transplanted into antibiotic-treated ApoE-/- mice. Body weight and glucose were measured weekly; mice were sacrificed at week 16 with blood, arterial, and intestinal tissue collected. Atherosclerotic lesion area was assessed by Oil Red O staining; inflammatory factors were analyzed by immunohistochemistry and qPCR; gut microbiota and metabolites were profiled by 16S rRNA sequencing and targeted metabolomics. Results: Compared with recipients of pre-treatment fecal samples (EC group), recipients of post-treatment samples (E group) showed slower weight gain, significantly reduced aortic atherosclerotic plaque area, and reduced cardiovascular inflammatory factors (ICAM-1, VCAM-1, IL-6, MCP-1). E group mice showed altered microbiota with a decreasing trend in genera with potential bile acid hydrolase activity; fecal conjugated bile acid levels were significantly elevated. The authors concluded that empagliflozin can attenuate weight gain, reduce aortic inflammatory factor expression, and reduce atherosclerotic plaque area via gut microbiota.

3. ADF and 5:2 Diets Improve Diabetic Neuropathy via Gut Microbiota and Metabolites

Authors: Xueli Yang, Xiaoyang Shi, Ya Xu, Junpeng Yang, Chenghong Liang, Jiaxin Xing, Xiudan Wang, Danyu Wang, Qinyuan Xie, Yiqi Chen, Yun Zhang, Huijuan Yuan (corresponding). Affiliation: Department of Endocrinology and Metabolism, Henan Provincial People’s Hospital.

Background: Intermittent fasting regimens, including alternate-day fasting (ADF) and 5:2 diet, can improve diabetes and central nervous system disorders, and are closely linked to gut microbiota. Distal symmetric polyneuropathy (DSPN) is the most common complication of diabetes; whether intermittent fasting improves DSPN and the underlying mechanisms remain unclear. Methods: Male db/db mice were randomized to ad libitum feeding, ADF, or 5:2 diet, with or without antibiotic treatment; causality was tested by fecal microbiota transplantation (FMT). 16S rRNA sequencing analyzed microbiota; LC-MS metabolomics assessed fecal metabolites; colonic tight junction proteins were examined to assess intestinal barrier integrity. Results: Both ADF and 5:2 diets improved peripheral neuropathy, restored intestinal barrier function, reduced systemic inflammation, and altered microbiota and metabolite levels. ADF enriched Lactobacillus murinus and Lachnospiraceae while reducing Muribaculaceae and Bacteroides acidifaciens. The 5:2 diet increased Lachnospiraceae and Mucispirillum and reduced Muribaculaceae and Alloprevotella. ADF increased beneficial metabolites such as N-acetylhistamine, asparagine, and butyrate, and decreased harmful N-acetylputrescine and phenylacetic acid. The 5:2 diet similarly increased N-acetylhistamine and reduced phenylacetic acid. After antibiotic-induced microbiota depletion, the neuroprotective effects of ADF and 5:2 diets disappeared. FMT from ADF- or 5:2-treated donors to pseudo-germ-free mice reduced harmful metabolites and re-improved neuropathy, barrier function, and inflammation. The authors concluded that ADF and 5:2 diets may alleviate DSPN through gut microbiota modulation, metabolite alteration, reduced inflammation, and barrier restoration, with comparable effects between the two regimens.

4. Global and Chinese Burden of EOD-Related CKD, 1990-2021

Authors: Xiaoyang Shi, Kai Zhang, Junpeng Yang, Xinru Deng, Lingyun Zhao, Qinyuan Xie, Huijuan Yuan (corresponding). Affiliation: Department of Endocrinology and Metabolism, Henan Provincial People’s Hospital; Department of General Medicine, the Third Affiliated Hospital of Zhengzhou University.

Background: T2D-related chronic kidney disease (CKD) is a major microvascular complication of T2D. With the rising prevalence of T2D and its earlier onset, the population with T2D onset at 15-39 years (early-onset T2D, EOD) is expanding, magnifying the public health impact of T2D-CKD. Methods: Analysis using Global Burden of Disease 2021 (GBD 2021) data, assessing EOD-CKD burden globally and in China. Joinpoint regression calculated annual percentage change (APC) of age-standardized rates (ASR) for incidence, prevalence, DALYs, and mortality, 1990-2021. Attributable risk factor analysis identified leading contributors; health inequality analyses examined differences across socio-demographic index (SDI) levels. Results: In 2021, global EOD-CKD prevalence was 20.9 million cases (approximately 3.44 million more than in 1990); China had 3.11 million cases (about 780,000 fewer than in 1990). Age-standardized rates of EOD-CKD burden showed a downward trend globally and in China. Beyond high fasting blood glucose, high body mass index (BMI) was the leading risk factor for EOD-CKD-related mortality and life expectancy, with a rising share (APC=1.29, 95% CI 1.14-1.43, P<0.001), most pronounced in China. Health inequalities were observed, with ASIR and ASPR inequalities concentrated in middle-SDI regions and ASDR inequalities mainly in high-SDI regions, with notable increases after 2010. The authors concluded that although global EOD-CKD burden declined from 1990 to 2021, the absolute number remains substantial. Overweight and obesity should be the primary prevention focus; high-income countries should focus on quality-of-life impacts, while lower-income regions should prioritize EOD-CKD prevention.

5. Sleep Duration, CKM Syndrome Stage, and Mortality: A Large Chinese Cohort

Authors: Xinru Deng, Yujia Zhai, Huijuan Yuan (corresponding). Affiliation: Department of Endocrinology and Metabolism, Henan Provincial People’s Hospital.

Background: The relationship between sleep duration, cardiometabolic-kidney (CKM) syndrome stage, and mortality has not been fully characterized. Methods: 12,674 participants from the China Health and Retirement Longitudinal Study (CHARLS), with a median 8.3-year follow-up. Restricted cubic spline regression explored nonlinear sleep-mortality associations; Cox proportional hazards regression estimated hazard ratios (HR) and 95% confidence intervals (CI) for CKM stage and sleep duration. Results: Among 12,674 participants aged 45 years or older (mean 59.5 ± 9.5 years; 48.0% male), sleep duration and mortality showed a near-U-shaped pattern (nonlinear P<0.05). After adjusting for confounders, short sleepers (<5 hr/night) had an all-cause mortality HR of 1.29 (95% CI 1.13-1.47) versus 6-8-hour sleepers. Late-stage CKM (stage 3-4) was associated with a 44% increased mortality risk versus early-stage CKM (stage 0-2). Subjects in late-stage CKM with <5 hours of sleep had significantly elevated mortality risk (HR 1.94, 95% CI 1.61-2.35). The authors concluded that short sleep and late-stage CKM are independent and possibly synergistic risk factors for all-cause mortality in this large Chinese population aged 45 years and older, and that improving sleep duration may help reduce associated mortality risk.

6. Non-Obese Adipocyte Immunity: Visceral Adipocytes Coordinate Early Host Defense in Peritoneal Infection

Authors: Yujin Ding, Dingding Wei, Tuo Deng (corresponding). Affiliations: Department of Endocrinology and Metabolism, the Second Xiangya Hospital, Central South University; Department of Endocrinology and Metabolism, Henan Provincial People’s Hospital.

Background: Following intestinal injury or perforation, visceral fat rapidly adheres to and envelops the damaged site; this is traditionally viewed as physical sealing. The study aimed to clarify whether adipocytes in adhering visceral fat actively participate in peritoneal infection defense. Methods: Mouse cecal puncture and TNBS intestinal injury models combined with visceral fat resection/transposition, neutrophil depletion, adipocyte-specific gene knockout, RNA sequencing, single-nucleus RNA sequencing, flow cytometry, and chemotaxis assays, with analysis of adhering omental samples from appendicitis patients. Results: Visceral fat adhesion correlated with higher survival; resection or transposition worsened bacterial dissemination and organ damage. Protection persisted after neutrophil depletion but infection worsened, indicating the protective role is not solely mechanical. Mechanistic studies showed that adhering adipocytes recruit neutrophils via the S100A8/A9-CD147-NF-kB-CXCL1 signaling axis, limiting bacterial spread; similar inflammatory changes were observed in human appendicitis omental samples. The authors concluded that visceral fat acts not only as a physical barrier but also as a local immune defense tissue after intestinal injury, with mature adipocytes actively recruiting protective neutrophils.

7. Intermittent vs Continuous Energy Restriction for Cardiovascular Risk Factors

Authors: Yiqi Chen, Ya Xu, Junpeng Yang, Fenglian Huang, Xueli Yang, Huijuan Yuan (corresponding). Affiliation: Department of Endocrinology and Metabolism, Henan Provincial People’s Hospital.

Background: Overweight, obesity, and related cardiovascular disease impose a heavy burden; energy restriction is the cornerstone of weight management. Intermittent energy restriction (IER), including alternate-day fasting (ADF), 5:2, and time-restricted eating (TRE, e.g., 16:8), is popular, but whether it is more effective than continuous energy restriction (CER) and which of the three regimens is superior remain unsettled. Methods: PubMed, Cochrane, and Web of Science were searched through September 2026, identifying 36 randomized controlled trials (RCTs) comparing IER with CER in adults with BMI>=25 (n=2,923). Random-effects models with subgroup, sensitivity, and GRADE analyses evaluated 14 cardiovascular risk factors. Results: Overall, IER reduced weight by an additional 1.02 kg and waist circumference by 0.90 cm versus CER, and lowered fasting insulin by 0.77 microIU/mL (all moderate-quality evidence), without significant loss of muscle mass. The three regimens differed (P=0.048): ADF produced the largest weight reduction (-1.83 kg) and improved lipids and insulin resistance; 5:2 reduced weight by 1.05 kg; TRE overall showed no clear advantage. The TRE result was driven down primarily by one 9-month study in adults over 60 years; without it, TRE reduced weight by approximately 1.05 kg with consistent results across studies, suggesting TRE may be less effective in older adults while remaining effective in younger populations. Findings were robust across multiple statistical methods. The authors concluded that in adults with overweight or obesity, IER (particularly ADF and 5:2) improved weight, waist circumference, and insulin versus CER. TRE is not ineffective but may be less suitable for older adults. Clinical choice should be individualized by age, adherence, and preference; whether long-term hard cardiovascular endpoints can be reduced requires further long-term RCTs.

Expert Profile: Prof. Huijuan Yuan

- Chief Physician and Professor; doctoral and postdoctoral supervisor; Central Plains Scholar

- Director, Department of Endocrinology and Metabolism, Henan Provincial People’s Hospital

- Head of National Clinical Key Specialty

- Chair, Henan Provincial Endocrine Medical Quality Control Center

- Director, Henan Provincial Obesity Diagnosis and Treatment Center

- Director, Henan Engineering Research Center for Diabetes Microecology Diagnosis, Treatment and Translation

- Standing Committee Member, Chinese Medical Association Endocrinology Branch

- Chair, Henan Medical Association Endocrinology Branch

- Chair, Henan Cardiovascular Metabolism Alliance

- Member, Standing Committee of the Henan Provincial People’s Congress

- National March 8th Red Banner Holder

- Principal investigator on 6 National Natural Science Foundation and National Key R&D Program projects; first-completer of 9 provincial-level awards including First Prize of Henan Provincial Science and Technology Progress Award; corresponding author of more than 100 SCI publications in journals including Cell Metabolism; participant in drafting more than 20 national guidelines/consensus statements

First Author Brief Profiles

Xiaoyang Shi

Associate Chief Physician, Department of Endocrinology and Metabolism, Henan Provincial People’s Hospital; Associate Professor

Xinru Deng

Associate Chief Physician, Department of Endocrinology and Metabolism, Henan Provincial People’s Hospital

Yalei Liu

Associate Chief Physician, Department of Endocrinology and Metabolism, Henan Provincial People’s Hospital

Yiqi Chen

Attending Physician, Department of Endocrinology and Metabolism, Henan Provincial People’s Hospital

Xueli Yang

Attending Physician, Department of Endocrinology and Metabolism, Henan Provincial People’s Hospital

Yujin Ding

Resident Physician, Department of Endocrinology and Metabolism, Henan Provincial People’s Hospital

Conclusion

The seven oral presentations reflect the team’s continued focus on gut microbiota and metabolic disease, spanning clinical epidemiology, mechanistic intervention, and translational exploration. Future work will continue advancing basic-to-clinical translation and exploring integrated “heart-kidney” prevention and microecology-targeted interventions for diabetes. Whether these signals translate into clinically meaningful outcomes will require further validation in larger, longer studies.

0
0
Loading